bluebird bio, Inc. (NASDAQ:BLUE) Receives $49.14 Consensus PT from Analysts

Shares of bluebird bio, Inc. (NASDAQ:BLUE) have been assigned a consensus recommendation of “Hold” from the nine brokerages that are presently covering the company, Marketbeat reports. Two analysts have rated the stock with a sell recommendation, five have given a hold recommendation and two have issued a buy recommendation on the company. The average 1-year price objective among brokers that have covered the stock in the last year is $49.14.

Several research firms have commented on BLUE. Barclays upped their price objective on bluebird bio from $2.00 to $40.00 and gave the company an “overweight” rating in a research note on Tuesday, December 31st. Bank of America cut bluebird bio from a “buy” rating to a “neutral” rating and cut their price target for the stock from $60.00 to $10.00 in a research note on Friday, November 15th. Wells Fargo & Company lowered their price objective on shares of bluebird bio from $60.00 to $40.00 and set an “equal weight” rating on the stock in a research report on Wednesday, September 25th. Royal Bank of Canada restated a “sector perform” rating and set a $80.00 price objective on shares of bluebird bio in a research report on Friday, November 15th. Finally, JPMorgan Chase & Co. downgraded shares of bluebird bio from a “neutral” rating to an “underweight” rating in a report on Friday, November 15th.

bluebird bio Price Performance

Shares of NASDAQ:BLUE opened at $8.01 on Friday. bluebird bio has a one year low of $5.80 and a one year high of $38.40. The stock has a market capitalization of $77.87 million, a price-to-earnings ratio of -4.28 and a beta of 0.68. The company has a 50-day simple moving average of $8.11 and a 200-day simple moving average of $12.36. The company has a debt-to-equity ratio of 0.37, a quick ratio of 0.33 and a current ratio of 0.51.

Institutional Trading of bluebird bio

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. State Street Corp increased its holdings in bluebird bio by 1.1% in the third quarter. State Street Corp now owns 3,841,923 shares of the biotechnology company’s stock valued at $1,996,000 after buying an additional 43,382 shares in the last quarter. Rhumbline Advisers grew its holdings in shares of bluebird bio by 25.4% in the 2nd quarter. Rhumbline Advisers now owns 292,436 shares of the biotechnology company’s stock worth $288,000 after acquiring an additional 59,219 shares during the period. SG Americas Securities LLC increased its stake in bluebird bio by 152.4% in the 3rd quarter. SG Americas Securities LLC now owns 122,855 shares of the biotechnology company’s stock valued at $64,000 after purchasing an additional 74,185 shares in the last quarter. Captrust Financial Advisors raised its holdings in bluebird bio by 48.2% during the third quarter. Captrust Financial Advisors now owns 237,648 shares of the biotechnology company’s stock worth $123,000 after purchasing an additional 77,293 shares during the last quarter. Finally, Verition Fund Management LLC purchased a new stake in bluebird bio during the third quarter worth $42,000. Institutional investors and hedge funds own 87.43% of the company’s stock.

About bluebird bio

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.